IACOVELLI, ROBERTO
 Distribuzione geografica
Continente #
NA - Nord America 1.267
EU - Europa 1.248
AS - Asia 877
SA - Sud America 97
Continente sconosciuto - Info sul continente non disponibili 43
AF - Africa 33
Totale 3.565
Nazione #
US - Stati Uniti d'America 1.221
RU - Federazione Russa 504
SG - Singapore 302
CN - Cina 299
GB - Regno Unito 261
IT - Italia 137
SE - Svezia 80
VN - Vietnam 77
BR - Brasile 72
HK - Hong Kong 68
IE - Irlanda 66
DE - Germania 62
FR - Francia 51
KR - Corea 27
CA - Canada 21
BD - Bangladesh 19
FI - Finlandia 18
MX - Messico 18
IN - India 16
NG - Nigeria 11
NL - Olanda 11
AR - Argentina 10
ID - Indonesia 10
JP - Giappone 9
PL - Polonia 9
UA - Ucraina 9
AT - Austria 6
MA - Marocco 6
TR - Turchia 6
UZ - Uzbekistan 6
ZA - Sudafrica 6
BE - Belgio 5
EC - Ecuador 5
ES - Italia 5
AZ - Azerbaigian 4
IQ - Iraq 4
PH - Filippine 4
CH - Svizzera 3
CZ - Repubblica Ceca 3
EG - Egitto 3
PK - Pakistan 3
PY - Paraguay 3
RS - Serbia 3
SA - Arabia Saudita 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
CL - Cile 2
CO - Colombia 2
GR - Grecia 2
GT - Guatemala 2
HR - Croazia 2
IL - Israele 2
JO - Giordania 2
KE - Kenya 2
TH - Thailandia 2
TN - Tunisia 2
AF - Afghanistan, Repubblica islamica di 1
AO - Angola 1
BG - Bulgaria 1
BH - Bahrain 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
GE - Georgia 1
GH - Ghana 1
HN - Honduras 1
HU - Ungheria 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LK - Sri Lanka 1
LT - Lituania 1
LU - Lussemburgo 1
LV - Lettonia 1
MK - Macedonia 1
MY - Malesia 1
NP - Nepal 1
OM - Oman 1
PA - Panama 1
PE - Perù 1
PR - Porto Rico 1
PS - Palestinian Territory 1
PT - Portogallo 1
SC - Seychelles 1
SI - Slovenia 1
TT - Trinidad e Tobago 1
TW - Taiwan 1
UY - Uruguay 1
VE - Venezuela 1
YE - Yemen 1
Totale 3.522
Città #
Southend 241
Ashburn 194
Moscow 171
Chandler 153
Singapore 149
San Jose 108
Dallas 75
Hong Kong 67
Dublin 66
Beijing 63
The Dalles 44
Ann Arbor 39
Verona 39
Council Bluffs 37
Los Angeles 32
Houston 30
New York 30
Jacksonville 28
Jinan 24
Nanjing 22
Santa Clara 21
Lawrence 20
Princeton 20
Wilmington 19
São Paulo 16
Ho Chi Minh City 15
Montreal 14
Shenyang 14
Helsinki 13
Hebei 12
Tianjin 12
Abuja 11
Dong Ket 11
Munich 11
Kent 10
Redwood City 10
Buffalo 9
Columbus 9
Dearborn 9
Hanoi 9
Redondo Beach 9
Guangzhou 8
Haikou 8
Mexico City 8
Rome 8
Taizhou 8
Tokyo 8
Seoul 7
Haiphong 6
Jakarta 6
Tashkent 6
Vienna 6
Warsaw 6
Brussels 5
Denver 5
Johannesburg 5
Lanzhou 5
Ningbo 5
Seattle 5
Sindelfingen 5
Amsterdam 4
Baku 4
Boston 4
Changsha 4
Chennai 4
Milan 4
Nanchang 4
Stockholm 4
Woodbridge 4
Belgrade 3
Belo Horizonte 3
Brooklyn 3
Buenos Aires 3
Cairo 3
Campinas 3
Chicago 3
Detroit 3
Falkenstein 3
Frankfurt am Main 3
Fuzhou 3
Hangzhou 3
Istanbul 3
Jiaxing 3
Louisville 3
Nave 3
New Delhi 3
Orem 3
Padua 3
Paris 3
Prague 3
Querétaro 3
Renton 3
Santiago 3
Taiyuan 3
Toronto 3
Zhengzhou 3
Agawam 2
Amman 2
Asunción 2
Athens 2
Totale 2.131
Nome #
LC3B and ph-S6K are both expressed in epithelioid and classic renal angiomyolipoma: a rationale tissue-based evidence for combining use of autophagic and mTOR targeted drugs 246
The Tumor Entity Denominated "clear cell-papillary renal cell carcinoma" According to the WHO 2016 new Classification, have the Clinical Characters of a Renal Cell Adenoma as does Harbor a Benign Outcome 218
The incidence and relative risk of pulmonary toxicity in patients treated with anti-PD1/PD-L1 therapy for solid tumors: a meta-analysis of current studies 213
The Cardiovascular Toxicity of Abiraterone and Enzalutamide in Prostate Cancer 205
Addressing the best treatment for non-clear cell renal cell carcinoma: A meta-analysis of randomised clinical trials comparing VEGFR-TKis versus mTORi-targeted therapies 204
Comparison Between Prognostic Classifications in De Novo Metastatic Hormone Sensitive Prostate Cancer 204
De novo metastatic castration sensitive prostate cancer: State of art and future perspectives 189
Renal cell carcinoma in one year: Going inside the news of 2017 - A report of the main advances in RCC cancer research 188
Wide spetcrum mutational analysis of metastatic renal cell cancer: a retrospective next generation sequencing approach 188
The development of PARP as a successful target for cancer therapy 181
Immunotherapy versus standard of care in metastatic renal cell carcinoma. A systematic review and meta-analysis 175
Metabolic phenotype of bladder cancer 167
Positive Association between Preoperative Total Testosterone Levels and Risk of Positive Surgical Margins by Prostate Cancer: Results in 476 Consecutive Patients Treated Only by Radical Prostatectomy 164
Inside the 2015 ASCO Genitourinary Cancers Symposium 160
Prostate cancer heterogeneity: Discovering novel molecular targets for therapy 155
Inside the 2016 American Society of Clinical Oncology Genitourinary Cancers Symposium: part 2 - prostate and bladder cancer 154
Inside the 2016 American Society of Clinical Oncology Genitourinary Cancers Symposium: part 1 - kidney cancer 149
Predictive role of changes in the tumor burden and International Metastatic Renal Cell Carcinoma Database Consortium class during active surveillance for metastatic renal cell carcinoma 142
Re: Ian D. Davis, Wanling Xie, Carmel Pezaro, et al. Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category. Eur Urol 2017;71:970-8: The Change in Baseline IMDC Prognostic Category: From the Past, Implications for the Future 136
Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer 127
Totale 3.565
Categoria #
all - tutte 11.994
article - articoli 11.994
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 23.988


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022124 0 39 2 2 16 5 1 10 3 5 2 39
2022/2023405 22 49 34 58 33 112 4 34 49 3 5 2
2023/2024184 5 18 7 16 42 22 3 18 0 9 39 5
2024/2025449 18 21 23 107 19 14 9 9 95 23 37 74
2025/20261.633 108 61 95 292 426 100 138 69 158 119 31 36
2026/202732 6 26 0 0 0 0 0 0 0 0 0 0
Totale 3.565